Adage Capital Partners
BIO icon

Adage Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Adage Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,610
Closed -$5.36M – 880
2024
Q2 		$5.36M Sell
19,610
-900
-4% -$262K 0.01% 706
2024
Q1 		$7.09M Buy
20,510
+200
+1% +$65.8K 0.01% 657
2023
Q4 		$6.56M Buy
20,310
+19,500
+2,407% +$6.11M 0.01% 656
2023
Q3 		$290K Sell
810
-20,500
-96% -$7.91M ﹤0.01% 791
2023
Q2 		$8.08M Sell
21,310
-9,765
-31% -$3.97M 0.02% 604
2023
Q1 		$14.9M Sell
31,075
-400
-1% -$187K 0.03% 512
2022
Q4 		$13.2M Sell
31,475
-39,900
-56% -$16.1M 0.03% 560
2022
Q3 		$29.8M Sell
71,375
-30,700
-30% -$15.3M 0.07% 296
2022
Q2 		$50.5M Buy
102,075
+34,900
+52% +$18.2M 0.12% 184
2022
Q1 		$37.8M Buy
67,175
+44,165
+192% +$26.6M 0.07% 286
2021
Q4 		$17.4M Sell
23,010
-100
-0.4% -$74.8K 0.03% 521
2021
Q3 		$17.2M Sell
23,110
-300
-1% -$225K 0.03% 518
2021
Q2 		$15.1M Sell
23,410
-210
-0.9% -$128K 0.03% 564
2021
Q1 		$13.5M Buy
23,620
+230
+1% +$136K 0.03% 585
2020
Q4 		$13.6M Sell
23,390
-610
-3% -$347K 0.03% 524
2020
Q3 		$12.4M Buy
24,000
+18,200
+314% +$9.22M 0.03% 491
2020
Q2 		$2.62M Buy
+5,800
New +$2.56M 0.01% 671
2018
Q4 		– Sell
-90,000
Closed -$28.2M – 711
2018
Q3 		$28.2M Buy
90,000
+10,000
+13% +$3.1M 0.06% 330
2018
Q2 		$23.1M Buy
80,000
+5,000
+7% +$1.38M 0.05% 371
2018
Q1 		$18.8M Sell
75,000
-18,500
-20% -$4.71M 0.04% 409
2017
Q4 		$22.3M Sell
93,500
-6,500
-7% -$1.58M 0.05% 382
2017
Q3 		$22.2M Buy
100,000
+49,978
+100% +$11.2M 0.05% 389
2017
Q2 		$11.3M Buy
+50,022
New +$10.9M 0.03% 545

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners's BIO Position: Q3 2024 in Review

Adage Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 19,610 shares — an estimated $5.36M sold.

Adage Capital Partners first reported a position in BIO in Q2 2017 and held it in 23 quarters. The position peaked at $50.5M in Q2 2022. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Adage Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Adage Capital Partners sold 19,610 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $5.36M.
  • Adage Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 23 quarters.
  • Adage Capital Partners's Bio-Rad Laboratories Class A position peaked at $50.5M in Q2 2022.
  • 438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Adage Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.